HRP20191491T1 - Biotin za liječenje demijelinizirajućih neuropatija - Google Patents
Biotin za liječenje demijelinizirajućih neuropatija Download PDFInfo
- Publication number
- HRP20191491T1 HRP20191491T1 HRP20191491T HRP20191491T1 HR P20191491 T1 HRP20191491 T1 HR P20191491T1 HR P20191491 T HRP20191491 T HR P20191491T HR P20191491 T1 HRP20191491 T1 HR P20191491T1
- Authority
- HR
- Croatia
- Prior art keywords
- biotin
- use according
- treatment
- patient
- daily amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Ceramics (AREA)
- Manufacture, Treatment Of Glass Fibers (AREA)
- Farming Of Fish And Shellfish (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305437.4A EP3072513A1 (en) | 2015-03-26 | 2015-03-26 | Biotin for treating Amyotrophic lateral sclerosis |
| PCT/EP2016/056696 WO2016151132A1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating amyotrophic lateral sclerosis |
| EP16713833.8A EP3273957B1 (en) | 2015-03-26 | 2016-03-25 | Biotin for treating demyelinating neuropathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191491T1 true HRP20191491T1 (hr) | 2019-11-15 |
Family
ID=52779582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191491 HRP20191491T1 (hr) | 2015-03-26 | 2016-03-25 | Biotin za liječenje demijelinizirajućih neuropatija |
Country Status (24)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
| EP3275439A1 (en) | 2016-07-29 | 2018-01-31 | Medday Pharmaceuticals | Method for treating hepatic encephalopathy |
| JP7537764B2 (ja) * | 2018-12-11 | 2024-08-21 | マイオスポッツ・オーストラリア・ピーティーワイ・リミテッド | 接着パッド |
| CN112386703A (zh) * | 2020-01-15 | 2021-02-23 | 李启芳 | 治疗als的联合用药物及其应用 |
| WO2022075913A1 (en) * | 2020-10-09 | 2022-04-14 | Tx Medic Ab | Treatment of muscle atrophy using dextran sulfate |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885976A (en) * | 1995-05-08 | 1999-03-23 | Sandyk; Reuven | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions |
| NZ565990A (en) | 2002-09-27 | 2009-10-30 | Biogen Idec Inc | Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta |
| US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
| US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| MX2012007365A (es) | 2009-12-23 | 2012-08-15 | Lupin Ltd | Composiciones farmaceuticas de liberacion lenta de iloperidona. |
| FR2993780B1 (fr) | 2012-07-26 | 2015-02-13 | Assist Publ Hopitaux De Paris | Methode de traitement de la sclerose en plaque |
| FR2958166B1 (fr) | 2010-04-06 | 2012-07-13 | Assist Publ Hopitaux De Paris | Compositions pharmaceutiques fortement dosees en biotine |
| AU2012245205B2 (en) * | 2011-04-21 | 2017-06-01 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
| PH12014500094A1 (en) * | 2011-07-13 | 2014-03-17 | Cytokinetics Inc | Combination als therapy |
| CA2910717C (en) | 2013-04-29 | 2021-01-26 | Assistance Publique - Hopitaux De Paris | Biotin for use in treating x-linked adrenoleukodystrophy |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| EP3072513A1 (en) | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
-
2015
- 2015-03-26 EP EP15305437.4A patent/EP3072513A1/en not_active Ceased
-
2016
- 2016-03-25 HR HRP20191491 patent/HRP20191491T1/hr unknown
- 2016-03-25 HU HUE16713833A patent/HUE046116T2/hu unknown
- 2016-03-25 MA MA41809A patent/MA41809B1/fr unknown
- 2016-03-25 PL PL16713833T patent/PL3273957T3/pl unknown
- 2016-03-25 AU AU2016238759A patent/AU2016238759B2/en not_active Ceased
- 2016-03-25 BR BR112017020408A patent/BR112017020408A2/pt not_active Application Discontinuation
- 2016-03-25 LT LT16713833T patent/LT3273957T/lt unknown
- 2016-03-25 KR KR1020177030427A patent/KR20170131543A/ko not_active Withdrawn
- 2016-03-25 SM SM20190548T patent/SMT201900548T1/it unknown
- 2016-03-25 EP EP16713833.8A patent/EP3273957B1/en active Active
- 2016-03-25 CA CA2980660A patent/CA2980660A1/en not_active Abandoned
- 2016-03-25 DK DK16713833T patent/DK3273957T3/da active
- 2016-03-25 SI SI201630372T patent/SI3273957T1/sl unknown
- 2016-03-25 ME MEP-2019-285A patent/ME03567B/me unknown
- 2016-03-25 CN CN201680018463.8A patent/CN107405335A/zh active Pending
- 2016-03-25 US US15/561,911 patent/US10357480B2/en not_active Expired - Fee Related
- 2016-03-25 WO PCT/EP2016/056696 patent/WO2016151132A1/en not_active Ceased
- 2016-03-25 ES ES16713833T patent/ES2748354T3/es active Active
- 2016-03-25 PT PT16713833T patent/PT3273957T/pt unknown
- 2016-03-25 CN CN202010704334.2A patent/CN111973592A/zh active Pending
- 2016-03-25 EA EA201792124A patent/EA034394B1/ru not_active IP Right Cessation
- 2016-03-25 RS RS20191089A patent/RS59149B1/sr unknown
- 2016-03-25 JP JP2018500860A patent/JP6752874B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-24 IL IL254619A patent/IL254619B/en active IP Right Grant
-
2019
- 2019-06-25 US US16/451,654 patent/US20190314342A1/en not_active Abandoned
- 2019-11-13 CY CY20191101195T patent/CY1122374T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191491T1 (hr) | Biotin za liječenje demijelinizirajućih neuropatija | |
| JP2015038135A5 (cg-RX-API-DMAC7.html) | ||
| JP2014111603A5 (cg-RX-API-DMAC7.html) | ||
| HRP20150260T1 (hr) | Uporaba biotina za lijeäśenje multiple skleroze | |
| HRP20241461T1 (hr) | Aprocitentan za uporabu u liječenju hipertenzije i povezanih bolesti u kombinaciji s valsartanom | |
| JP2015083580A5 (cg-RX-API-DMAC7.html) | ||
| JP2018530578A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530706A5 (cg-RX-API-DMAC7.html) | ||
| MX2020012377A (es) | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. | |
| JP2018522028A5 (cg-RX-API-DMAC7.html) | ||
| NZ737561A (en) | Oral composition of celecoxib for treatment of pain | |
| PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| JP2018512451A5 (cg-RX-API-DMAC7.html) | ||
| JP2019518022A5 (cg-RX-API-DMAC7.html) | ||
| JP2021505669A5 (cg-RX-API-DMAC7.html) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| HRP20191798T1 (hr) | Postupak liječenja jetrene encefalopatije | |
| JP2019522030A5 (cg-RX-API-DMAC7.html) | ||
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| JP2015516451A5 (cg-RX-API-DMAC7.html) | ||
| JP2017515858A5 (cg-RX-API-DMAC7.html) | ||
| MX387263B (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma. | |
| MX2018015759A (es) | Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo. | |
| JP2017530142A5 (cg-RX-API-DMAC7.html) |